Vanguard Group
YARW

Vanguard Group’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Vanguard Group’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$182K Buy
6,291
+2,483
+65% +$49.8K ﹤0.01% 4118
2025
Q3 		$63.8K Sell
3,808
-6,118
-62% -$200K ﹤0.01% 4269
2025
Q2 		$819K Buy
9,926
+413
+4% +$26.8K ﹤0.01% 3795
2025
Q1 		$752K Buy
9,513
+10
+0.1% +$1.23K ﹤0.01% 3789
2024
Q4 		$1.59M Buy
9,503
+633
+7% +$82.8K ﹤0.01% 3632
2024
Q3 		$834K Hold
8,870
– – ﹤0.01% 3825
2024
Q2 		$874K Buy
8,870
+7,477
+537% +$932K ﹤0.01% 3836
2024
Q1 		$214K Buy
1,393
+401
+40% +$43.2K ﹤0.01% 4168
2023
Q4 		$116K Buy
992
+94
+10% +$14.6K ﹤0.01% 4285
2023
Q3 		$181K Hold
898
– – ﹤0.01% 4270
2023
Q2 		$184K Buy
898
+141
+19% +$37.5K ﹤0.01% 4323
2023
Q1 		$117K Sell
757
-1,077
-59% -$193K ﹤0.01% 4390
2022
Q4 		$248K Buy
1,834
+1
+0.1% +$200 ﹤0.01% 4268
2022
Q3 		$368K Sell
1,833
-168
-8% -$53.8K ﹤0.01% 4297
2022
Q2 		$700K Buy
2,001
+357
+22% +$150K ﹤0.01% 4198
2022
Q1 		$962K Sell
1,644
-852
-34% -$506K ﹤0.01% 4219
2021
Q4 		$2.29M Sell
2,496
-211
-8% -$226K ﹤0.01% 3989
2021
Q3 		$3.39M Hold
2,707
– – ﹤0.01% 3867
2021
Q2 		$8.55M Sell
2,707
-59
-2% -$234K ﹤0.01% 3291
2021
Q1 		$17M Buy
2,766
+671
+32% +$4.86M ﹤0.01% 2864
2020
Q4 		$11.9M Buy
2,095
+130
+7% +$817K ﹤0.01% 2903
2020
Q3 		$11.7M Buy
1,965
+20
+1% +$117K ﹤0.01% 2708
2020
Q2 		$12.1M Buy
1,945
+1,662
+587% +$11.3M ﹤0.01% 2669
2020
Q1 		$2.73M Buy
283
+136
+93% +$2.13M ﹤0.01% 3214
2019
Q4 		$2.46M Sell
147
-1
-0.7% -$16.7K ﹤0.01% 3389
2019
Q3 		$2.38M Sell
148
-7
-5% -$113K ﹤0.01% 3392
2019
Q2 		$3.35M Buy
155
+6
+4% +$148K ﹤0.01% 3306
2019
Q1 		$4.21M Buy
149
+105
+239% +$2.52M ﹤0.01% 3197
2018
Q4 		$653K Sell
44
-83
-65% -$1.86M ﹤0.01% 3675
2018
Q3 		$4.52M Buy
127
+54
+74% +$1.67M ﹤0.01% 3275
2018
Q2 		$2.13M Buy
73
+17
+30% +$661K ﹤0.01% 3479
2018
Q1 		$7.62M Buy
+56
New +$6.81M ﹤0.01% 2959

Other funds holding YARW

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group's YARW Position: Q4 2025 in Review

Vanguard Group increased its Yarrow Bioscience, Inc. Common Stock (YARW) stake by 65% in Q4 2025, buying an estimated $49.8K and bringing the position to 6,291 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #4118.

Vanguard Group first reported a position in YARW in Q1 2018 and has held it in 32 quarters since. The position peaked at $17M in Q1 2021. 41 funds tracked by Wall St. Rank hold YARW as of Q4 2025.

  • Vanguard Group held 6,291 shares of Yarrow Bioscience, Inc. Common Stock worth $182K as of Q4 2025.
  • Vanguard Group bought 2,483 Yarrow Bioscience, Inc. Common Stock shares in Q4 2025, an estimated $49.8K.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4118 holding.
  • Vanguard Group first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and has held it in 32 quarters since.
  • Vanguard Group's Yarrow Bioscience, Inc. Common Stock position peaked at $17M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.